Highest-materiality recent filing
VRM provided a one-time $250,000 advance to MSP Recovery for operating expenses per an approved budget.
MSP Recovery securities to move to OTC Expert Market on July 17 due to delayed filings
Company has not filed 10-K for 2025 or 10-Q for Q1 2026 with the SEC.
MSP Recovery receives $0.2M discretionary advance from Hazel; no further funding committed
Hazel made a one-time $208,000 advance on June 26, 2026, increasing the Operational Collection Floor to $8,355,500 aggregate.
MSP Recovery receives $0.1M advance from Hazel Partners under existing credit facility
One-time advance of $0.1M funded June 12, 2026, for operating expenses.
MSP Recovery gets $0.1M Hazel advance & $0.12M VRM advances; requires CRO appointment
Hazel Partners advances $0.1M one-time under Operational Collection Floor; no further funding commitment.
MSP Recovery gets $188K in emergency advances; stock downgraded to OTC Pink
OTC Markets downgraded MSPR to OTC Pink effective May 20, 2026 due to delinquent Form 10-K filing.
Hazel advanced $137,500 under Working Capital Credit Facility; total Operational Collection Floor now $7.862M.
Hazel Partners advanced $117,500 under the Operational Collection Floor on April 16, 2026; no further funding available.
MSP Recovery obtains $0.2M in one-time advances; discloses no further committed liquidity
Hazel Partners advanced $125,000 under existing working capital facility; total Operational Collection Floor raised to $7.607M.
MSP Recovery secures $150k in emergency advances; liquidity remains highly constrained
Hazel Partners made a discretionary $75k advance under the Operational Collection Floor, now at ~$7.48M; no further funding committed.
MSP Recovery loses director and CFO; obtains two $0.2M emergency advances
Director Ophir Sternberg resigned Feb 13; CFO Francisco Rivas-Vasquez resigned Feb 17. Neither departure due to disagreements.
MSP Recovery secures $250K discretionary advance from Hazel; no committed funding remains
Hazel Partners advanced $250K on Jan 26, 2026 under the Operational Collection Floor; total increases now $7.207M since Mar 2025.
MSP Recovery gets $300K discretionary advance from Hazel; total floor $6.9M
Hazel advanced $300K on Jan 20, 2026 for operating expenses under one-time discretionary accommodation.
Delisted from Nasdaq on Dec 22, 2025; now trades on OTCQB.
MSP Recovery obtains $325k discretionary advance from Hazel; no further funding available
One-time $325k advance under operational collection floor for operating expenses; funded by Jan 9, 2026.
MSP Recovery furloughs 33% of workforce; public warrants moved to OTCID Basic
Public warrants (MSPRW) transferred to OTCID Basic Market effective Jan 6, 2026, after Nasdaq delisting.
MSP Recovery COO Ricardo Rivera departs effective Dec 22, 2025; will advise through year-end
Ricardo Rivera is no longer employed as COO as of December 22, 2025.
Nasdaq Panel denies MSPR appeal; common stock delisted Dec 22, moves to OTCQB
On Dec 18, 2025, Nasdaq Hearings Panel denied appeal; suspension effective Dec 22, 2025.
SEC concludes investigation of MSP Recovery without recommending enforcement action
SEC staff informed company on Dec 5, 2025 that investigation ended with no intention to recommend enforcement against company, CEO John H. Ruiz, or officers.
MSP Recovery receives additional Nasdaq delisting notice for bid price; hearing Dec 11
Additional staff determination: bid price below $1 for 30 consecutive days, non-compliant with Listing Rule 5550(a)(2).
MSP Recovery receives Nasdaq delisting notice; Yorkville floor price cut to $0.50
Nasdaq delisting determination received Oct 22, 2025; trading suspended Oct 31 unless hearing requested by Oct 29. Company intends to appeal.
MSP Recovery secures $3M Yorkville convertible note, floor price cut to $1; GC resigns
Yorkville agrees to advance up to $3M in convertible notes with 10% OID; net principal increase per advance capped at $1M.
MSP Recovery reduces Yorkville SEPA floor price to $1.20 per share from $1.60
Floor price under Yorkville Standby Equity Purchase Agreement reduced from $1.60 to $1.20 per share.
MSP Recovery enters two confidential settlements totaling $2.9M in cash
Mediated settlement with P&C insurer includes cash payment, data sharing, and cooperation on Medicare claims.
MSP Recovery reduces floor price under Yorkville equity line from $2.00 to $1.60
Floor price under Yorkville SEPA and Notes reduced from $2.00 to $1.60 per share, effective September 15, 2025.
MSP Recovery settles Cano Health litigation; all claims dismissed with prejudice
Settlement agreement executed on September 8, 2025, between MSP Recovery, LLC and Cano Health, LLC.
MSP Recovery lowers floor price under Yorkville SEPA from $3.50 to $2.00 per share
Floor price reduced to $2.00 per share effective September 5, 2025.
MSP Recovery signs non-binding term sheet for up to $55M secured delayed draw loan facility
Tranche A up to $10M (initial $5M funded at close; $5M discretionary).
MSP Recovery effects 1-for-7 reverse stock split to regain Nasdaq compliance
Reverse split approved Aug 18, effective Sept 1, 2025 at 11:59 PM.
Jury awards $12.7M against MSP Recovery LLC; company and CEO exonerated on fraud claims
Jury exonerated MSP Recovery, Inc. and CEO John H. Ruiz on all fraud and misrepresentation claims.
MSP Recovery shareholders approve reverse stock split and warrant exercise shares
Approved Charter amendment for reverse stock split at ratio between 1:2 and 1:7; Board selects final ratio.
MSP Recovery issues $750K convertible note to Yorkville; annual meeting reelects directors
Issued sixth convertible note to Yorkville for $0.75M, net proceeds ~$0.71M after OID; disbursed in two $0.36M advances on Aug 8 and Aug 15.
MSP Recovery lowers SEPA floor price to $0.50 from $1.00
Floor Price under Yorkville SEPA reduced to $0.50 per share, effective August 5, 2025.
MSP Recovery issues $0.75M convertible note to Yorkville; replaces auditor Deloitte with Baker Tilly
Issued fifth convertible note for $0.75M under SEPA; net proceeds $0.71M; 5% interest, convertible at 95% of 5-day VWAP (floor $1.00), maturity March 2027.
Maryland Supreme Court upholds MSP Recovery's assignments, allowing GEICO class action to proceed
Maryland's highest court unanimously ruled assignments from Medicare Advantage Organizations are valid and not champertous.
MSP Recovery amends Nomura note to ~$33.6M, issues $0.75M Yorkville convertible note
Amended Nomura note to ~$33.6M principal; Nomura waives up to $3M of Yorkville SEPA proceeds.
MSP Recovery restructuring term sheet terminated by Hazel and Virage; floor price reduced to $1.00
Hazel terminated Apr 10 term sheet on May 30 citing missed definitive-agreement deadline; funded $0.8M advance on June 2.
Nomura note principal raised to $32.7M (from $30.0M), maturity extended to November 30, 2026.
MSP Recovery receives Nasdaq delisting notice; stockholders' equity negative $128M
Nasdaq notified MSP Recovery of non-compliance with minimum stockholders' equity requirement.
Virage Recovery waives ~$1.2B claim in exchange for 43% equity stake in the Company.
MSP Recovery term sheet with Virage to issue 33.3% of Class A stock to settle MTA obligations
Virage may exercise warrants to acquire 33 1/3% of outstanding Class A common stock at $0.0025/share.
MSP Recovery defers Yorkville monthly payment, commits to weekly share issuances
First Monthly Payment under Yorkville Notes deferred to no sooner than April 30, 2025.
MSP Recovery transfers listing from Nasdaq Global Market to Capital Market effective Dec 10, 2024
Received Nasdaq approval to transfer common stock listing to Nasdaq Capital Market.
MSP Recovery to consolidate brands; stock ticker changes to MSPR on Dec 9
Effective December 9, 2024, the company consolidates all business lines under the MSP Recovery brand.
MSP Recovery regains Nasdaq compliance, reports $2M pharma settlement and Nomura waiver
Nasdaq confirmed bid price deficiency cured; Class A common stock continues listing on Nasdaq Global Market.
Preliminary $2.0M settlement for RICO and consumer protection claims; includes non-monetary data to pursue 12+ other pharma firms.
MSP Recovery completes 1-for-25 reverse stock split; Nomura waives $4M in repayment requirements
Effective Nov 15, 2024, every 25 shares of Class A and Class V common stock combined into one, reducing Class A shares from ~46.7M to ~1.9M.
MSP Recovery/LifeWallet settles P&C claims for $5.9M; launches clearinghouse beta with Palantir
Two P&C insurer settlements total >$5.2M; includes 10-yr data sharing and assignment of recovery rights.
MSP Recovery issues 109.7M warrants to VRM at $0.0001/share
Issued warrants to purchase 43,380,152 shares (Sep 2024) and 66,322,033 shares (Oct 2024) to VRM.
MSP Recovery draws $9M at 40% OID; Hazel waives 2024 going-concern default trigger
Drew $7M of $14M working capital (40% OID) and $2M for claims acquisition (40% OID) under amended credit line.
Mr. Ricardo Rivera will no longer serve as the Company’s interim CFO, although Mr. Rivera will continue to serve as the Company’s Chief Operating Officer.
On November 1, 2023, MSP Recovery, Inc. d/b/a LifeWallet’s (the “Company” or “LifeWallet”) Board of Directors (the “Board”) appointed Francisco Rivas-Vásquez, C.P.A., as the Company’s Chief Financial Officer (“CFO”) and principal financial officer.
On June 29, 2023, the board of directors appointed Ricardo Rivera, age 51, as interim Chief Financial Officer of the MSP Recovery, Inc. (the “Company”), effective immediately.
On June 28, 2023, Calvin Hamstra tendered his resignation as Chief Financial Officer of the Company to the board of directors of the Company.
Mr. Ricardo Rivera will no longer serve as the Company’s principal financial officer.
On June 24, 2022, the Company’s Board of Directors (the “Board”) appointed Calvin Hamstra, 36, as the Company’s Chief Financial Officer and principal financial officer.
On July 5, 2021, the Board appointed Faquiry Diaz Cala to the position of Chief Operating Officer.
On July 5, 2021, the Board appointed Thomas Hawkins to fill the Board vacancy created by Mr. Barran’s resignation.
On July 4, 2021, Trevor Barran, the Chief Operating Officer of Lionheart Acquisition Corporation II (the “ Company ”) and a member of the Company’s board of directors (the “ Board ”) , notified the Chairman of the Board of his resignation from the Board and all other positions with the Company, effective immediately.
On June 25, 2021 and June 29, 2021, respectively, the Board appointed James Anderson and Thomas Byrne (together, the “ New Directors ”) to fill the Board vacancies noted above.
On June 25, 2021, Aman Kapadia, a member of the Board and a member of the Audit Committee and Compensation Committee, notified the Chairman of the Board of his resignation from the Board, effective immediately.
On June 25, 2021 and June 29, 2021, respectively, the Board appointed James Anderson and Thomas Byrne (together, the “ New Directors ”) to fill the Board vacancies noted above.
Max materiality 0.90 · Median 0.62 · Most common event other_material